Merck announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended the approval of gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist, developed for the treatment for adults with refractory or unexplained chronic cough. The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union and a final decision is expected later this year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Pfizer price target lowered to $42 from $43 at Morgan Stanley
- Merck price target lowered to $116 from $118 at Truist
- Merck announces Phase 3 KEYNOTE-A18 trial met one primary endpoint
- Johnson & Johnson Stock (NYSE:JNJ): Medicare Negotiations and Q2 Earnings in Focus
- Merck price target raised to $113 from $102 at BMO Capital